Oral and Poster Abstracts
Oral
711. Cell Collection and Processing: Hematopoietic Stem/Progenitor Cells Graft and Immune Effector Cells
Elke Rücker-Braun, PhD1,2*, Bose Falk1*, Kate A. Markey, MBBS, PhD, FRACP, MPH3,4, Hans Minderman5*, Henning Baldauf1*, Nicole Heymann1*, Heike Uhlemann1*, Lisa Heiduschke1*, Hugh R. MacMillan6*, Evan W. Newell, PhD6*, Kieran L. O'Loughlin7*, Ashley Spahn8*, Orla Maguire5*, Deborah Buk9*, Martin Bornhäuser, MD10,11*, Alexander H. Schmidt, Dr.1*, Steven M. Devine, MD12, Johannes Schetelig, MD, MSc1,11, Jeffery J. Auletta, MD8,13, Marcel R.M. van den Brink14, Stephen R. Spellman, MBS8* and Falk Heidenreich, PhD2,15*
1DKMS Group gGmbH, Dresden, Germany
2University Hospital Dresden, Dresden, Germany
3Division of Medicine, University of Washington, Seattle, WA
4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
5Flow and Image Cytometry Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, NY
6Fred Hutchinson Cancer Center, Seattle, WA
7Flow and Immune Analysis Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, NY
8CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN
9DKMS Donor Center gGmbH, Tübingen, Germany
10National Center for Tumor Diseases (NCT/UCC) Dresden, Technical University Dresden, Dresden, Germany
11Department of Internal Medicine 1, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
12Be the Match Foundation, Minneapolis, MN
13Hematology/Oncology/Bone Marrow Transplant and Infectious Diseases, Nationwide Children's Hospital, Columbus, OH
14Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
15DKMS Ggmbh, Clinical Trials Unit, Dresden, Germany
The impact of the cellular composition of PBSC grafts on the immune reconstitution as well as graft-versus-host and graft-versus-leukemia effects after allogeneic hematopoietic cell transplantation (alloHCT) is only poorly understood. DKMS and NMDP joined forces to comprehensively characterize the cellular composition of 2,000 PBSC products using a 34-color flow cytometry panel to define immune effector cell subsets of interest and hematopoietic stem cells. In parallel, we have created a biobank of unstimulated donor PBMC and PBSC graft samples for future analyses. As part of this larger effort, we investigated the effect of cryopreservation on the cellular composition of PBSC products. Cryopreservation of PBSC grafts was used frequently during the COVID19-pandemic and facilitated more flexible timelines for transplantation. Still, one third of the US patients and 15% of the German patients continue to receive cryopreserved PBSC grafts. Ongoing studies are investigating the impact of cryopreservation on immune-effector cell function and the outcome of hematopoietic stem cell transplantation. Several observational studies have reported delayed neutrophil and platelet engraftment with cryopreserved products. More recently, less chronic GVHD was reported for patients who had received cryopreserved PBSC products. Cryopreservation affects the cellular composition and hence has the potential to change immune effector cell functions of the graft, but available data on the alterations of cell population frequencies are scarce. We analyzed the cellular composition of 20 fresh grafts and compared them to their frozen and thawed counterparts. Cryopreservation of product samples followed routine clinical procedures using a 10% DMSO containing cryo-medium and a controlled rate freezing. After thawing at 37°C, cells were washed, stained with a 34-parameter phenotyping panel, fixed and analyzed immediately on a full spectrum flow cytometer. Following spectral unmixing and manual spillover correction, proportions of immune cells were assessed using manual gating. First, we investigated the relative frequencies of 10 non-overlapping individual cell populations relative to viable CD45+ cells, including several lymphocyte populations, monocytes, granulocytes, hematopoietic stem cells (HSC) and dendritic cells. Granulocytes showed the largest decrease after cryopreservation and thawing (18.2 % vs 3.5 %; p<0.001). The loss of granulocytes results in an increase of relative frequencies of many other immune cell populations including monocytes (35.4 % vs 44.7 %; p=0.018), B cells (5.8 % vs 9.6 %; p=0.006), and HSC (1.0 % vs 1.5 %; p<0.001). We therefore also calculated changes relative to the viable non-granulocyte cells. By doing so, a significant relative increase of cells was observed for HSC (1.2 % vs 1.6 %; p<0.001), whereas monocyte and B cell frequencies changed only marginally. This suggests that HSC are more resilient to freezing than other cell types. When comparing the proportions of 40 other immune cell (sub‑) populations relative to their parent population in the gating hierarchy, we found a profound and significant decrease of the relative frequencies for CD16+ myeloid dendritic cells (mDCs, 68 % vs 30 % of all mDCs; p<0.001) and granulocytic myeloid derived suppressor cells (gMDSCs, 2 % vs 1 % of all MDSCs; p<0.001). In an independent set of analyses performed at Roswell Park Comprehensive Cancer Center, Buffalo, comparable results were obtained with a significant increase of HSC, a significant decrease of CD16+ mDCs, and a trend of a decrease of gMDSCs. As CD16+ mDCs may have a role in the development of chronic GVHD after alloHCT, this decrease may be meaningful. In summary, we found that cryopreservation of PBSC allografts resulted in a decreased relative frequency of granulocytes, and CD16+ mDCs, as well as an increased relative frequency of HSCs. The results provide some insight into the impact of cryopreservation on PBSC graft composition and warrant further efforts to explore the potential mechanisms for the differential outcomes observed using fresh vs cryopreserved PBSCs.
Disclosures: Markey: Postbiotics Plus: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy; Crestone: Consultancy. Newell: Neogene Therapuetics: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Immunoscape: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Nanostring Technologies: Membership on an entity's Board of Directors or advisory committees. Schetelig: Abbvie: Consultancy, Honoraria; BeiGene: Consultancy, Honoraria; Eurocept: Honoraria; BMS: Consultancy, Honoraria; Novartis: Honoraria; AstraZeneca: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Auletta: National Marrow Donor Program: Current Employment; Takeda: Membership on an entity's Board of Directors or advisory committees; AscellaHealth: Membership on an entity's Board of Directors or advisory committees. van den Brink: Thymofox: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Ceramedix: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; DKMS (a non-profit organization): Membership on an entity's Board of Directors or advisory committees; Pluto Immunotherapeutics: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees; Notch Therapeutics: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees; Wolters Kluwer: Patents & Royalties; Juno Therapeutics: Other: IP licensing; Seres Therapeutics: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: IP licensing , Research Funding; Rheos Medicines: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Frazier Healthcare Partners: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Lygenesis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Vor Biopharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Nektar Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Da Volterra: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.
*signifies non-member of ASH